We are live on ! Find out more
PCVX icon

Vaxcyte
PCVX

251 hedge funds and large institutions have $8.13B invested in Vaxcyte in 2024 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 102 increasing their positions, 77 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 18

37% more call options, than puts

Call options by funds: $16.7M | Put options by funds: $12.2M

32% more repeat investments, than reductions

Existing positions increased: 102 | Existing positions reduced: 77

25% more capital invested

Capital invested by funds: $6.51B → $8.13B (+$1.63B)

13% more funds holding

Funds holding: 223 → 251 (+28)

0.97% more ownership

Funds ownership: 108.91% → 109.87% (+0.97%)

14% less funds holding in top 10

Funds holding in top 10: 14 → 12 (-2)

Holders
251
Holders Change
+28
Holders Change %
+12.56%
% of All Funds
3.62%
Holding in Top 10
12
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-14.29%
% of All Funds
0.17%
New
48
Increased
102
Reduced
77
Closed
18
Calls
$16.7M
Puts
$12.2M
Net Calls
+$4.53M
Net Calls Change
-$2.42M

Top Buyers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$160M
2
DGM
Darwin Global Management
Jersey
+$150M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$142M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$89M
5
PBA
Paradigm Biocapital Advisors
New York
+$85.9M

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$40.5M
2
Millennium Management
Millennium Management
New York
-$33.5M
3
VPC
Vestal Point Capital
New York
-$33M
4
GPP
Great Point Partners
Connecticut
-$22.6M
5
Pictet Asset Management
Pictet Asset Management
Switzerland
-$19.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
PC
76
Pier Capital
Connecticut
$8.7M -$5.14M -74,178 -37%
Rafferty Asset Management
77
Rafferty Asset Management
New York
$8.62M -$2.23M -32,249 -20%
CS
78
Credit Suisse
Switzerland
$8.47M +$1.81M +26,167 +27%
Manulife (Manufacturers Life Insurance)
79
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$8.13M +$970K +14,009 +13%
MAP
80
Moody Aldrich Partners
Massachusetts
$8.1M -$2.03M -29,325 -20%
Ameriprise
81
Ameriprise
Minnesota
$8.1M +$5.26M +76,008 +179%
Capstone Investment Advisors
82
Capstone Investment Advisors
New York
$7.47M +$7.57M +109,389 New
UBS AM
83
UBS AM
Illinois
$7.38M +$1.84M +26,539 +33%
ACP
84
Acuta Capital Partners
California
$7.16M -$869K -12,543 -11%
PAMP
85
Polar Asset Management Partners
Ontario, Canada
$7.14M -$7.6M -109,800 -51%
SEI Investments
86
SEI Investments
Pennsylvania
$7.06M +$3.81K +55 +0.1%
Neuberger Berman Group
87
Neuberger Berman Group
New York
$6.99M +$1.12M +16,144 +19%
MIM
88
Monashee Investment Management
Massachusetts
$6.83M +$4.33M +62,500 +167%
GTC
89
Ghost Tree Capital
New York
$6.49M +$1.73M +25,000 +36%
Legal & General Group
90
Legal & General Group
United Kingdom
$6.47M +$1.02M +14,780 +18%
California State Teachers Retirement System (CalSTRS)
91
California State Teachers Retirement System (CalSTRS)
California
$6.29M +$671K +9,695 +12%
NIP
92
Nicholas Investment Partners
California
$5.85M -$1.74M -25,079 -23%
Adage Capital Partners
93
Adage Capital Partners
Massachusetts
$5.81M -$4.5M -65,000 -43%
OM
94
Opaleye Management
Massachusetts
$5.81M -$346K -5,000 -6%
AAA
95
Affinity Asset Advisors
New York
$5.46M +$3.81M +55,000 +220%
AA
96
ALPS Advisors
Colorado
$5.21M +$763K +11,021 +17%
AGP
97
Artia Global Partners
Florida
$5.21M +$2.61M +37,700 +98%
CM
98
Castleark Management
Illinois
$5.13M -$708K -10,220 -12%
RJA
99
Raymond James & Associates
Florida
$4.53M +$1.02M +14,779 +29%
First Trust Advisors
100
First Trust Advisors
Illinois
$4.36M -$956K -13,810 -18%
2 3
4
5 6

PCVX Hedge Fund Activity: Q1 2024 in Review

251 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q1 2024, worth a combined $8.13B — up 25% from $6.51B a quarter earlier.

Buyers outnumbered sellers: 48 funds opened new PCVX positions and 18 closed out — a net gain of 30 holders — while 102 added to existing stakes and 77 trimmed.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $160M. The largest seller was Morgan Stanley, cutting an estimated $40.5M.

  • 251 institutional investors held Vaxcyte (PCVX) as of Q1 2024, up from 223 in Q4 2023.
  • Funds reported $8.13B of Vaxcyte stock for Q1 2024, up 25% quarter-over-quarter.
  • 48 funds opened new Vaxcyte positions in Q1 2024 and 18 closed out, a net change of +30 holders.
  • The largest Vaxcyte buyer in Q1 2024 was T. Rowe Price Investment Management, an estimated $160M added.
  • The largest Vaxcyte seller in Q1 2024 was Morgan Stanley, an estimated $40.5M sold.

Based on aggregated 13F filings for Q1 2024.